NOVEN ANNOUNCES 2007 THIRD QUARTER EARNINGS RELEASE DATE |
BackMiami, FL, November
2, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
its 2007 third quarter earnings release date.
On November 8th, before the U.S. market opens, Noven is scheduled to
issue a press release announcing its financial results for the three
and nine month periods ended September 30, 2007. At 9:00 a.m. Eastern
Time the same day, a conference call with management will be broadcast
live via the Internet at www.noven.com, and thereafter a rebroadcast
will be accessible at the same site for at least two weeks. A taped replay
of the call will be available beginning November 8th through November
10th by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from
outside the U.S.) and entering account number 286 and conference ID number
258318.
About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami,
Florida, has established itself as a leading developer of advanced transdermal
drug delivery technologies and prescription transdermal products. Its
commercialized transdermal products include Vivelle-Dot® (estradiol
transdermal system), the most prescribed estrogen patch in the U.S.,
and Daytrana™ (methylphenidate transdermal system), the first and
only patch approved for the treatment of ADHD.
With the acquisition of
JDS Pharmaceuticals in August 2007, Noven has become a broader-based
specialty pharmaceutical company with the infrastructure, products and
category expertise to market and sell products itself, and with a substantially
enhanced late-stage product pipeline.
Products currently marketed through
the JDS psychiatry sales infrastructure consist of Pexeva® (paroxetine
mesylate) and Lithobid® (lithium carbonate). Pipeline products in
psychiatry consist of Stavzor™ (delayed release valproic acid capsule),
Lithium QD (once-daily lithium carbonate), and Stavzor™ ER (extended
release valproic acid capsule). Pipeline products in women’s health
consist of Mesafem™ (low-dose paroxetine mesylate), a non-hormonal
product entering Phase 3 clinical trials for vasomotor symptoms (hot
flashes). See www.noven.com for additional information.
Contact:
|
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.